Category: Mazor Robotics Ltd.
Mazor Robotics rakes in nearly $47 million from a $17-per-share stock offering after the underwriters trigger an over-allotment worth about $6 million.
Mazor Robotics (NSDQ:MZOR) said it raked in a total of $46.9 million from a stock offering announced last week, including a last-minute $5.9 million addition from an over-allotment.
The Caesarea, Israel-based robotics company makes the Renaissance robotic surgery system for spinal surgeries.
Mazor Robotics pricing a stock offering at $17 per share, saying the total proceeds could approach $41 million.
Mazor Robotics (NSDQ:MZOR) said it plans to offer 2.4 million shares of stock at $17 apiece, for total proceeds of $40.8 million.
Shares of Mazor Robotics slide after the medical device company reports a nearly 27% slide in 3rd-revenues and announces a planned public offering of up to 2.3 million shares.
Third-quarter revenues for Mazor Robotics (NSDQ:MZOR) are expected to slide nearly 27%, the Israeli medical device company said, adding that it's planning an offering of up to 2.3 million shares of its stock.
Bay State medical device maker Accellent promotes Jeremy Friedman from his role as CFO to president & COO.
Accellent names new COO, president
Massachusetts medtech manufacturer Accellent Inc. shuffled its C-Suite, promoting Jeremy Friedman from CFO to president and COO of the cardio & vascular business, in addition to his duties as executive vice president.
Mazor Robotics' Renaissance robot-assisted surgical system treats its 1st Parkinson's patient with a deep-brain stimulation implant.
MASSDEVICE ON CALL — For the 1st time Mazor Robotics' (PINK:MZRTF) Renaissance robot-assisted surgical system system was used to to treat a Parkinson's patient, implanting a battery-sized neurostimulator that delivers mild electrical stimulation to targeted areas of the brain.
Orthofix delays filing its 2nd-quarter financials and says it will restate its books for the past 2 years due to improperly recognized revenues.
Orthofix (NSDQ:OFIX) said an audit of its books is prompting it to restate its financial results for 2011, 2012 and Q1 2013 after discovering revenues that were improperly recognized.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you're still in the know with MassDevice +3.